Eli Lilly

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Eli Lilly 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About LLY

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. 

CEO
David A. Ricks
CEODavid A. Ricks
Employees
50,000
Employees50,000
Headquarters
Indianapolis, Indiana
HeadquartersIndianapolis, Indiana
Founded
1876
Founded1876
Employees
50,000
Employees50,000

LLY Key Statistics

Market cap
1.19T
Market cap1.19T
Price-Earnings ratio
41.07
Price-Earnings ratio41.07
Dividend yield
0.55%
Dividend yield0.55%
Average volume
2.30M
Average volume2.30M
High today
$1,274.56
High today$1,274.56
Low today
$1,253.00
Low today$1,253.00
Open price
$1,256.00
Open price$1,256.00
Volume
1.33M
Volume1.33M
52 Week high
$1,292.65
52 Week high$1,292.65
52 Week low
$783.85
52 Week low$783.85

Stock Snapshot

With a market cap of 1.19T, Eli Lilly(LLY) trades at $1,260.17. The stock has a price-to-earnings ratio of 41.07 and currently yields dividends of 0.55%.

During the trading session on 2026-10-16, Eli Lilly(LLY) shares reached a daily high of $1,274.56 and a low of $1,253.00. At a current price of $1,260.17, the stock is +0.6% higher than the low and still -1.1% under the high.

Trading activity shows a volume of 1.33M, compared to an average daily volume of 2.3M.

The stock's 52-week range extends from a low of $783.85 to a high of $1,292.65.

The stock's 52-week range extends from a low of $783.85 to a high of $1,292.65.

LLY News

Benzinga 3h
Eli Lilly's GLP-1 Pill Wins Key European Backing for Obesity and Diabetes

The Committee for Medicinal Products for Human Use (CHMP) on Friday issued a positive opinion, recommending marketing authorization for a new medication aimed a...

Eli Lilly's GLP-1 Pill Wins Key European Backing for Obesity and Diabetes
TipRanks 4h
EMA adopts positive opinion on Eli Lilly’s Foundayo, recommending approval

On October 15, the Committee for Medicinal Products for Human Use adopted a positive opinion, recommending the granting of a marketing authorization for the med...

Quartz 6h
Eli Lilly's Foundayo weight-loss pill gets E.U. panel backing - Quartz

...

Eli Lilly's Foundayo weight-loss pill gets E.U. panel backing - Quartz

Analyst ratings

85%

of 33 ratings
Buy
84.8%
Hold
9.1%
Sell
6.1%

More LLY News

Simply Wall St 6h
Top 3 Biotech Stocks To Watch In October 2026

Bond markets are flashing warnings, with 10 year US Treasury yields recently crossing 5.3% for the first time since 2002. When borrowing costs feel this heavy,...

Top 3 Biotech Stocks To Watch In October 2026
The Motley Fool 7h
Eli Lilly's Biggest Shareholder Is Selling $347 Million of Stock. Should You Sell Too?

The largest shareholder of Eli Lilly (LLY +3.55%) is selling 300,000 shares of the giant drugmaker, which would have a market value of $347 million (at the time...

Eli Lilly's Biggest Shareholder Is Selling $347 Million of Stock. Should You Sell Too?
Simply Wall St 7h
Eli Lilly Shares In Focus After Omvoh Shows Deep Remission In Crohn’s

Eli Lilly (NYSE:LLY) reported new Omvoh data showing corticosteroid-free disease control in ulcerative colitis patients with prior biologic failure. The same r...

Eli Lilly Shares In Focus After Omvoh Shows Deep Remission In Crohn’s
The Motley Fool 1d
Stock Split Watch: Is Eli Lilly Next?

Eli Lilly (LLY +4.82%), as a pharmaceutical stock, may be seen as a source of safety for investors — patients need their medicines, and this provides a certain...

Stock Split Watch: Is Eli Lilly Next?
TipRanks 1d
Lilly Targets KRAS G12C in Colorectal Cancer With New Phase 2 Trial

Eli Lilly And Company (LLY) announced an update on their ongoing clinical study. The study, run by Eli Lilly And Company (LLY), is a Phase 2 trial called “A St...

TipRanks 1d
Lilly’s Donanemab Moves Into India: What This New Alzheimer’s Study Means for Investors

Eli Lilly And Company (LLY) announced an update on their ongoing clinical study. The Phase 4 study “A Phase 4, Multicenter, Open-Label, Single-Arm Study to Eva...

TipRanks 1d
Lilly’s Lebrikizumab Eczema Study Wraps Up, Adding Real‑World Support to Its Immunology Story

Eli Lilly And Company (LLY) announced an update on their ongoing clinical study. The Phase 4 study A Phase 4, Multicenter, Open-label, Single-arm Study to Inve...

People also own

Based on the portfolios of people who own LLY. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.